Media coverage about Neurocrine Biosciences (NASDAQ:NBIX) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.7192938991272 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) opened at 61.82 on Tuesday. Neurocrine Biosciences has a 12 month low of $37.35 and a 12 month high of $61.98. The company’s 50 day moving average price is $56.19 and its 200 day moving average price is $50.07. The company’s market cap is $5.45 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.01). The business had revenue of $6.34 million during the quarter, compared to analyst estimates of $0.61 million. During the same period in the prior year, the business posted ($0.46) EPS. On average, equities analysts expect that Neurocrine Biosciences will post ($2.44) EPS for the current fiscal year.

A number of analysts have recently weighed in on the stock. Robert W. Baird reaffirmed an “outperform” rating and set a $66.00 price target on shares of Neurocrine Biosciences in a report on Thursday, September 21st. BidaskClub upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $70.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, July 5th. Cowen and Company restated an “outperform” rating and set a $65.00 target price (up from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. Finally, ValuEngine upgraded Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Two analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $68.25.

COPYRIGHT VIOLATION WARNING: This piece was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/neurocrine-biosciences-nbix-earning-somewhat-positive-news-coverage-report-shows/1604201.html.

In other news, insider Haig P. Bozigian sold 22,500 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $50.00, for a total value of $1,125,000.00. Following the completion of the transaction, the insider now owns 154,601 shares of the company’s stock, valued at approximately $7,730,050. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Dimitri E. Grigoriadis sold 15,354 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $55.00, for a total value of $844,470.00. Following the completion of the transaction, the insider now owns 123,045 shares of the company’s stock, valued at approximately $6,767,475. The disclosure for this sale can be found here. In the last quarter, insiders sold 125,655 shares of company stock worth $7,018,148. 4.80% of the stock is currently owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.